© 2026 Forbes Media LLC. All Rights Reserved.
© 2026 Forbes Media LLC. All Rights Reserved.
Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide ...
Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Recursion Pharmaceuticals (RXRX) ended the recent trading session at $3.53, demonstrating a +2.02% change from the preceding day's closing price. This move outpaced the S&P 500's daily gain of 0.56%.
Hosted on MSN
Recursion Pharmaceuticals (RXRX) falls more steeply than broader market: What investors need to know
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.85, moving -3.27% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.33%. On ...
I start most workdays with a trip to the gym. But then I sit, writing stories, and forget to get up for hours. I know that all that sitting isn't great for my health, and I can feel my hips and ...
The pharmaceutical market, worth $1.7 trillion, offers stable long-term investment opportunities. Top pharma stocks like AbbVie and Pfizer are poised for growth despite patent challenges. Invest in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results